logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Cardiology & Vascular drugs

    FiltersReset Filters
    39 results

    • adempas

      (riociguat)
      Bayer HealthCare Pharmaceuticals Inc.
      Usage: Adempas is indicated for adults with chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or if inoperable, as well as for pulmonary arterial hypertension (PAH). It improves exercise capacity, WHO functional class, and delays clinical worsening. The drug is effective as monotherapy or in combination with other treatments.

    • asclera

      (POLIDOCANOL)
      Methapharm, Inc
      Usage: Asclera® (polidocanol) is indicated for the sclerotherapy of uncomplicated spider veins (≤1 mm) and reticular veins (1 to 3 mm) in the lower extremities. It is not approved for use in varicose veins greater than 3 mm in diameter.

    • astagraf xl

      (tacrolimus extended-release capsules)
      Astellas Pharma US, Inc.
      Usage: ASTAGRAF XL® is indicated for the prevention of organ rejection in kidney transplant patients, used in conjunction with other immunosuppressants for both adults and pediatric patients who can swallow capsules intact.

    • atorvaliq

      (ATORVALIQ)
      CMP Pharma, Inc.
      Usage: ATORVALIQ is indicated to reduce the risk of cardiovascular events in adults with risk factors for coronary heart disease, type 2 diabetes, and clinically evident coronary heart disease. It also lowers LDL cholesterol in various conditions, including primary hyperlipidemia and familial hypercholesterolemia, as an adjunct to diet or other therapies.

    • benicar

      (olmesartan medoxomil)
      Cosette Pharmaceuticals, Inc.
      Usage: Benicar is indicated for treating hypertension in adults and children aged six and older to lower blood pressure, reducing the risk of cardiovascular events like strokes and heart attacks. It can be used alone or with other antihypertensive medications as part of comprehensive cardiovascular risk management.

    • benicar hct

      (olmesartan medoxomil-hydrochlorothiazide)
      Cosette Pharmaceuticals, Inc.
      Usage: BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension to lower blood pressure. It is not intended for initial therapy and may be used alone or with other antihypertensive medications to reduce cardiovascular risk, including strokes and myocardial infarctions.

    • caduet

      (amlodipine besylate and atorvastatin calcium)
      Pfizer Laboratories Div Pfizer Inc
      Usage: CADUET (amlodipine and atorvastatin) is indicated for patients requiring both hypertension management and lipid control. Amlodipine treats high blood pressure and various types of angina, while atorvastatin reduces risk of cardiovascular events and lowers LDL cholesterol in hyperlipidemia.

    • cleviprex

      (clevipidine)
      Chiesi USA, Inc.
      Usage: Cleviprex is indicated for lowering blood pressure in situations where oral medication is not feasible or desirable.

    • corlanor

      (ivabradine)
      Amgen Inc
      Usage: Corlanor is indicated to reduce hospitalization risk for adults with stable, symptomatic chronic heart failure (left ventricular ejection fraction ≤ 35%) and resting heart rate ≥ 70 bpm. It is also used for pediatric patients aged 6 months and older with stable symptomatic heart failure due to dilated cardiomyopathy.

    • eliquis

      (apixaban)
      E.R. Squibb & Sons, L.L.C.
      Usage: ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, as well as for the prophylaxis and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). It also reduces the risk of recurrence of DVT and PE post-therapy.